Table 1.
HLA class I and II antigens in white anti-HMGCR myopathy patients and white controlsa
| HLA | anti-HMGCR (%) n=20 | controls (%) n=487 | OR (95% CI) | p value |
|---|---|---|---|---|
| Class I | ||||
|
| ||||
| A2 | 10 (50) | 243 (50) | 1.0 (0.4–2.7) | 1.0 |
|
| ||||
| A3 | 7 (35) | 139 (29) | 1.3 (0.5–3.7) | 0.6 |
|
| ||||
| B35 | 6 (30) | 83 (17) | 2.1 (0.7–6.0) | 0.1 |
|
| ||||
| B44 | 9 (45) | 129 (26) | 2.3 (0.8–6.1) | 0.08 |
|
| ||||
| B60 | 5 (25) | 51 (10) | 2.9 (0.9–8.8) | 0.06 |
|
| ||||
| Class II | ||||
| DR4 | 8 (40) | 164 (34) | 1.3 (0.5–3.5) | 0.6 |
|
| ||||
| DR7 | 7 (35) | 138 (28) | 1.4 (0.5–3.8) | 0.6 |
|
| ||||
| DR11 | 14 (70) | 89 (18) | 10.4 (3.6–31.4) | 1.2 × 10−6 b |
|
| ||||
| DR15 | 0 (0) | 138 (28) | 0 (0.0–0.6) | 0.003 |
|
| ||||
| DQA1 | 5 (25) | 315 (64) | 0.2 (0.1–0.5) | 5.5 × 10−4 b |
|
| ||||
| DQA2 | 7 (35) | 137 (28) | 1.4 (0.5–3.8) | 0.6 |
|
| ||||
| DQA3 | 9 (45) | 171 (35) | 1.5 (0.6–4.0) | 0.5 |
|
| ||||
| DQA5 | 15 (75) | 194 (40) | 4.5 (1.5–14.5) | 0.0022 b |
|
| ||||
| DQB2 | 7 (35) | 174 (36) | 1.0 (0.3–2.7) | 1.0 |
|
| ||||
| DQB5 | 5 (25) | 133 (27) | 0.9 (0.3–2.7) | 1.0 |
|
| ||||
| DQB6 | 0 (0) | 217 (45) | 0.0 (0.0–0.3) | 2.1 × 10−5 b |
|
| ||||
| DQB7 | 15 (75) | 172 (35) | 5.5 (1.8–17.6) | 5.5 × 10−4 b |
|
| ||||
| DQB8 | 5 (25) | 108 (22) | 1.2 (0.4–3.5) | 0.8 |
|
| ||||
| DR11;DQA5;DQB7 | 14 (70) | 81 (17) | 11.7 (4.0–35.3) | 4.1 × 10−7 |
Abbreviations: CI = confidence interval; HLA = human leukocyte antigen; OR = odds ratio.
a
Set of alleles with frequency >20% in either patients or controls was analyzed by Fisher exact test.
b
p < 0.00277 was considered significant using the Bonferroni correction for n = 18 comparisons.